Related Experiment Video
Updated: Oct 29, 2025

Assessment of Vascular Function in Patients With Chronic Kidney Disease
Published on: June 16, 2014
Atherosclerotic Vascular Disease Associated with Chronic Kidney Disease
Matthew J Tunbridge1, Alan G Jardine2
1Nephrology Department, Royal Brisbane and Women's Hospital, Level 9 Ned Hanlon Building, Butterfield Street, Herston, QLD 4029, Australia; University of Queensland, Mayne Medical Building, 288 Herston Road, Herston, QLD 4029, Australia.
Insights
Cardiovascular risk significantly rises with declining kidney function, especially in end-stage renal disease. Slowing renal decline or transplantation are key to reducing cardiovascular disease in chronic kidney disease patients.
Area of Science:
- Nephrology and Cardiovascular Medicine
- Renal Disease Pathophysiology
- Cardiovascular Risk Stratification
Background:
- Cardiovascular disease (CVD) risk escalates with decreasing glomerular filtration rate (GFR) in progressive renal disease.
- Hyperlipidemia is a primary risk factor for atherosclerotic vascular disease (ASVD), a common comorbidity in patients with renal impairment.
- Dyslipidemia patterns and their association with vascular events become less clear as GFR declines.
Purpose of the Study:
- To examine the relationship between declining GFR and cardiovascular risk in renal disease.
- To investigate the challenges in managing dyslipidemia and ASVD in advanced chronic kidney disease (CKD).
- To identify effective strategies for reducing ASVD in CKD patients.
Main Methods:
- Review of existing literature on GFR, dyslipidemia, and cardiovascular outcomes in renal disease.
- Analysis of pathophysiological changes in CKD affecting lipid metabolism and vascular health.
- Evaluation of therapeutic interventions for ASVD in early, advanced, and end-stage CKD.
Main Results:
- Cardiovascular risk is maximal in end-stage renal disease patients requiring dialysis.
- Statin therapy demonstrates reduced effectiveness in advanced and end-stage CKD.
- Coronary interventions carry a greatly increased risk in CKD patients.
Conclusions:
- Slowing the decline of renal function is a critical strategy to mitigate ASVD in CKD.
- Renal transplantation offers a means to restore renal function and potentially reduce cardiovascular risk.
- Management of cardiovascular risk in advanced CKD requires tailored approaches beyond standard lipid-lowering therapies.
Abstract:
Cardiovascular risk increases as glomerular filtration rate (GFR) declines in progressive renal disease and is maximal in patients with end-stage renal disease requiring maintenance dialysis. Atherosclerotic vascular disease, for which hyperlipidemia is the main risk factor and lipid-lowering therapy is the key intervention, is common. However, the pattern of dyslipidemia changes with low GFR and the association with vascular events becomes less clear. While the pathophysiology and management of patients with early chronic kidney disease (CKD) is similar to the general population, advanced and end-stage CKD is characterized by a disproportionate increase in fatal events, ineffectiveness of statin therapy, and greatly increased risk associated with coronary interventions. The most effective strategies to reduce atherosclerotic cardiovascular disease in CKD are to slow the decline in renal function or to restore renal function by transplantation.
Related Concept Videos
Chronic Kidney Disease I: Introduction
Chronic Kidney Disease II: Clinical Manifestations
Peripheral Artery Disease I: Introduction
Chronic Kidney Disease III: Interprofessional Care
Nephrons
Chronic Kidney Disease IV: Nursing Management

